Skip to main content

Table 1 Baseline characteristics before and after propensity score matching

From: Trophectoderm biopsy is associated with adverse obstetric outcomes rather than neonatal outcomes

Characteristic

Before PSM

 

After PSM

 

PGT group

Control group

P value

PGT group

Control group

P value

(n = 223)

(n = 497)

 

(n = 215)

(n = 385)

 

Maternal age (years)

31.1 ± 4.3

31.1 ± 3.8

0.921

31.1 ± 4.3

31.1 ± 3.8

0.965

BMI (kg/m2)

22.2 ± 2.9

22.0 ± 3.1

0.272

22.1 ± 2.7

22.0 ± 3.2

0.778

Maternal parity (nulliparous)

173 (77.6)

410 (82.5)

0.120

165 (76.7)

301 (78.2)

0.685

Paternal age (years)

32.7 ± 5.8

32.8 ± 5.1

0.783

32.8 ± 5.8

32.7 ± 4.9

0.857

Duration of infertility, n (%)

  

0.131

  

0.356

 1–2

136 (61.0)

273 (54.9)

 

131 (60.9)

220 (57.1)

 

 3–5

59 (26.5)

169 (34.0)

 

58 (27.0)

125 (32.5)

 

  ≥ 6

28 (12.6)

55 (11.1)

 

26 (12.1)

40 (10.4)

 

Cause of infertility, n (%)

  

0.114

  

0.180

 Female

115 (51.6)

269 (54.1)

 

113 (52.6)

205 (53.2)

 

 Male

21 (9.4)

24 (4.8)

 

20 (9.3)

19 (4.9)

 

 Combined

82 (36.8)

196 (39.4)

 

77 (35.8)

154 (40.0)

 

 Unknown

5 (2.2)

8 (1.6)

 

5 (2.3)

7 (1.8)

 

Reason of PGT, n (%)

 PGT-A

138 (61.9)

/

 

133 (61.9)

/

 

 PGT-SR

73 (32.7)

/

 

70 (32.6)

/

 

 PGT-M

12 (5.4)

/

 

12 (5.6)

/

 

Previous history

 Smoking

0 (0.0)

3 (0.6)

0.556

0 (0.0)

2 (0.5)

0.539

 PCOS

22 (9.9)

70 (14.1)

0.117

21 (9.8)

54 (14.0)

0.130

 Diabetes

0 (0.0)

2 (0.4)

1.000

0 (0.0)

1 (0.3)

1.000

 Hypertension

1 (0.4)

3 (0.6)

1.000

1 (0.5)

2 (0.5)

1.000

 Thyroid dysfunction

23 (10.3)

35 (7.0)

0.136

23 (10.7)

27 (7.0)

0.117

 Autoimmune disease

6 (2.7)

8 (1.6)

0.383

6 (2.8)

6 (1.6)

0.365

 Recurrent pregnancy loss

68 (30.5)

19 (3.8)

 < 0.001

67 (31.2)

16 (4.2)

 < 0.001

 Repeated implantation failure

2 (0.9)

1 (0.2)

0.228

2 (0.9)

1 (0.3)

0.293

Hormone levels

 Basal FSH (mIU/mL)

7.6 ± 2.1

7.7 ± 2.3

0.848

7.6 ± 2.1

7.6 ± 2.3

0.892

 Basal LH (mIU/mL)

5.1 ± 3.0

5.3 ± 3.2

0.479

5.1 ± 3.0

5.4 ± 3.3

0.310

 Basal E2 (pg/mL)

44.9 ± 23.8

46.7 ± 26.7

0.380

45.0 ± 23.9

47.7 ± 28.3

0.229

 AMH (ng/mL)

5.5 ± 4.4

5.6 ± 4.2

0.701

5.6 ± 4.4

5.8 ± 4.4

0.509

Cycle rank, n (%)

  

0.385

  

0.301

 1

148 (66.4)

346 (69.6)

 

142 (66.1)

270 (70.1)

 

 2

75 (33.6)

151 (30.4)

 

73 (34.0)

115 (29.9)

 

Endometrial preparation, n (%)

  

0.020

  

0.893

 NC

47 (21.1)

146 (29.4)

 

47 (21.9)

86 (22.3)

 

 AC

176 (78.9)

351 (70.6)

 

168 (78.1)

299 (77.7)

 

Endometrial thickness (mm)

9.0 ± 1.5

9.5 ± 1.8

 < 0.001

9.0 ± 1.5

9.2 ± 1.5

0.203

Embryo developmental stage, n (%)

  

0.001

  

0.151

 D5

121 (54.3)

336 (67.6)

 

120 (55.8)

238 (61.8)

 

 D6

102 (45.7)

161 (32.4)

 

95 (44.2)

134 (38.2)

 

Good-quality embryo, n (%)

161 (72.2)

401 (80.7)

0.011

161 (74.9)

300 (77.9)

0.398

  1. Abbreviation: PGT preimplantation genetic testing, PSM propensity score matching, BMI body mass index, PGT-A preimplantation genetic testing for aneuploidy, PGT-SR preimplantation genetic testing for structural rearrangements, PGT-M preimplantation genetic testing for monogenic disorders, PCOS polycystic ovarian syndrome, FSH follicle-stimulating hormone, LH luteinizing hormone, E2 estradiol, AMH anti-Müllerian hormone, NC natural cycle, AC artificial cycle. A good-quality embryo was day 5 or 6 blastocyst grading 3BB or higher (AA, AB, BA, BB) before vitrification according to the grading scale proposed by Gardner. Data are presented as mean ± SD or n (%)
Back to article page

BMC Pregnancy and Childbirth

ISSN: 1471-2393

Contact us